CVS Health reaffirms FY2023 GAAP EPS $6.90-$7.12 and Adj. EPS $8.50-$8.70

CVS HEALTH Corp

Reaffirms full-year 2023 GAAP diluted EPS guidance range of $6.90 to $7.12.
Reaffirms Adjusted EPS guidance range of $8.50 to $8.70 and cash flow from operations of $12.5B-$13.5B.
Expects medical costs to remain in line with pricing; slightly >50% of earnings in H2 2023 with Q3 modestly higher than Q4.
Guidance unchanged from prior announcement; no new financial results reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.